Eli Lilly & Co. Global External R&D-Asia VP Tony Zhang On Lilly's FIPNET Strategies In China
This article was originally published in The Pink Sheet Daily
Zhang discusses Lilly's strategies in an interview with PharmAsia News' Shanghai bureau editors.
You may also be interested in...
Eli Lilly is deepening its commitment to China and diabetics in the country by opening a new R&D center in Shanghai that aims to discover novel compounds that will lead to breakthrough therapies for diabetes
Eli Lilly announced Oct. 18 that it will shut the doors of its eight-year-old Lilly Singapore Center for Drug Discovery
Lilly’s $6.5 billion acquisition of ImClone will create an oncology “powerhouse” with 18 cancer drugs in clinical development.